PMID- 37321028
OWN - NLM
STAT- MEDLINE
DCOM- 20230710
LR  - 20231118
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 200
DP  - 2023 Aug 1
TI  - Hypoattenuated Leaflet Thickening After Implantation of the ACURATE neo or the 
      ACURATE neo2 Transcatheter Heart Valve.
PG  - 146-152
LID - S0002-9149(23)00328-4 [pii]
LID - 10.1016/j.amjcard.2023.05.038 [doi]
AB  - Subclinical leaflet thrombosis, identified as hypoattenuated leaflet thickening 
      (HALT) on cardiac computed tomography scan, has been observed after transcatheter 
      aortic valve replacement (TAVR). However, data on HALT after the implant of the 
      supra-annular ACURATE neo/neo2 prosthesis are limited. This study aimed to 
      determine the prevalence and risk factors for the development of HALT after TAVR 
      with the ACURATE neo/neo2. A total of 50 patients who received the ACURATE 
      neo/neo2 prosthesis were prospectively enrolled. Patients underwent a 
      contrast-enhanced multidetector row cardiac computed tomography scan at before, 
      after, and 6 months after TAVR. At the 6-month follow-up, HALT was detected in 
      16% (8 of 50 patients). These patients had a lower implant depth of the 
      transcatheter heart valve (8 +/- 2 mm vs 5 +/- 2 mm, p = 0.001), less calcified 
      native valve leaflets, a better expansion of the frame at the level of the left 
      ventricular outflow tract, and were less often hypertensive. Thrombosis of the 
      sinus of Valsalva occurred in 18% (9/50). There was no difference in the 
      anticoagulation regimen between patients with and without thrombotic findings. In 
      conclusion, HALT was present in 16% of patients at 6 months follow-up, patients 
      presenting with HALT had a lower implant depth of the transcatheter heart valve, 
      and HALT was detected in patients on oral anticoagulation therapy.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Brunner, Stephanie
AU  - Brunner S
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Brinkert, Miriam
AU  - Brinkert M
AD  - Department of Cardiology, Kantonsspital Aarau, Aarau, Switzerland.
FAU - Moccetti, Federico
AU  - Moccetti F
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Loretz, Lucca
AU  - Loretz L
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Fornaro, Jurgen
AU  - Fornaro J
AD  - Department of Radiology, Luzerner Kantonsspital, Lucerne, Switzerland.
FAU - Stampfli, Simon F
AU  - Stampfli SF
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Attinger-Toller, Adrian
AU  - Attinger-Toller A
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Bossard, Matthias
AU  - Bossard M
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Buhmann, Ralf
AU  - Buhmann R
AD  - Department of Radiology, Luzerner Kantonsspital, Lucerne, Switzerland.
FAU - Cuculi, Florim
AU  - Cuculi F
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Wolfrum, Mathias
AU  - Wolfrum M
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland.
FAU - Toggweiler, Stefan
AU  - Toggweiler S
AD  - Cardiology Division, Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, 
      Switzerland. Electronic address: stefan.toggweiler@luks.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230613
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - IM
CIN - Am J Cardiol. 2023 Aug 15;201:378-381. PMID: 37468396
MH  - Humans
MH  - *Heart Valve Prosthesis/adverse effects
MH  - Treatment Outcome
MH  - Aortic Valve/surgery
MH  - *Transcatheter Aortic Valve Replacement/adverse effects/methods
MH  - Prosthesis Design
MH  - *Thrombosis/diagnostic imaging/epidemiology/etiology
MH  - *Aortic Valve Stenosis/surgery/etiology
COIS- Declaration of Competing Interest Dr. Toggweiler is a consultant and proctor for 
      Boston Scientific, Medtronic, Edwards Lifesciences, Abbott, and Biosensors; a 
      consultant for Medira, Atheart Medical, Veosource, Shockwave, Teleflex, Polares 
      Medical, Cardiac Dimensions, ReCor Medical; has received institutional research 
      grants from Boston Scientific, Novartis, and Fumedica AG; and holds equity in 
      Hi-D Imaging. Dr. Stampfli has received consulting, proctoring, or speaker fees 
      from Abbott, Alnylam, Amgen, AstraZeneca, Bayer-Myers Squibb, Fumedica, Novartis, 
      Polares Medical, Pfizer, and Takeda. Dr. Bossard received speaker and consulting 
      fees from Abbott Vascular, Abiomed, and SIS Medical. Dr. Wolfrum is a proctor for 
      Biosensors. The remaining authors have no conflicts of interest to declare.
EDAT- 2023/06/16 01:08
MHDA- 2023/07/10 06:42
CRDT- 2023/06/15 18:05
PHST- 2023/01/16 00:00 [received]
PHST- 2023/04/28 00:00 [revised]
PHST- 2023/05/21 00:00 [accepted]
PHST- 2023/07/10 06:42 [medline]
PHST- 2023/06/16 01:08 [pubmed]
PHST- 2023/06/15 18:05 [entrez]
AID - S0002-9149(23)00328-4 [pii]
AID - 10.1016/j.amjcard.2023.05.038 [doi]
PST - ppublish
SO  - Am J Cardiol. 2023 Aug 1;200:146-152. doi: 10.1016/j.amjcard.2023.05.038. Epub 
      2023 Jun 13.